I Mary Poynten1, Fengyi Jin1, Jennifer M Roberts2, David J Templeton3,4, Carmella Law5, Alyssa M Cornall6,7,8, Monica Molano6, Dorothy A Machalek6,9, Andrew Carr5, Annabelle Farnsworth2, Sepehr Tabrizi6, Samuel Phillips6, Christopher K Fairley9, Suzanne M Garland6,7,8, Richard J Hillman5, Andrew E Grulich1. 1. The Kirby Institute, University of New South Wales, New South Wales, Australia. 2. Douglass Hanly Moir Pathology, New South Wales, Australia. 3. RPA Sexual Health Service, Sydney Local Health District, Sydney, New South Wales, Australia. 4. Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia. 5. St Vincent's Hospital, Darlinghurst, New South Wales Australia. 6. Women's Centre for Infectious Disease, Royal Women's Hospital Melbourne, Parkville, Victoria, Australia. 7. Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, Victoria, Australia. 8. Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Victoria, Australia. 9. Melbourne Sexual Health Centre and Central Clinical School, Monash University, Victoria, Australia.
Abstract
BACKGROUND: Gay and bisexual men (GBM) are disproportionately affected by anal cancer. Prevention is hindered by incomplete understanding of the natural history of its precursor, anal high-grade squamous intraepithelial lesions (HSIL). METHODS: The Study of the Prevention of Anal Cancer, conducted between 2010 and 2018, enrolled human immunodeficiency virus (HIV)-positive and HIV-negative GBM aged ≥35 years. Anal cytology and high-resolution anoscopy (HRA) were performed at baseline and 3 annual visits. A composite HSIL diagnosis (cytology ± histology) was used. Cytological high-grade squamous intraepithelial lesions (cHSIL) incidence and clearance rates were calculated with 95% confidence intervals (CIs). Predictors were calculated using Cox regression with hazard ratios (HRs) and 95% CIs. RESULTS: Among 617 men, 220 (35.7%) were HIV-positive, median age 49 years. And 124 incident cHSIL cases occurred over 1097.3 person-years (PY) follow-up (11.3, 95% CI 9.5-13.5 per 100 PY). Significant bivariate predictors of higher incidence included age <45 years (HR 1.64, 95% CI 1.11-2.41), HIV positivity (HR 1.43, 95% CI .99-2.06), prior SIL diagnosis (P-trend < .001) and human papillomavirus (HPV)16 (HR 3.39, 2.38-4.84). Over 695.3 PY follow-up, 153 HSIL cleared (clearance 22.0, 95% CI 18.8-25.8 per 100 PY). Predictors were age < 45 years (HR 1.52, 1.08-2.16), anal intraepithelial neoplasia (AIN)2 rather than AIN3 (HR 1.79, 1.29-2.49), smaller lesions (HR 1.62, 1.11-2.36) and no persistent HPV16 (HR 1.72, 1.23-2.41). There was 1 progression to cancer (incidence 0.224, 95% CI .006-1.25 per 100 PY). CONCLUSION: These data strongly suggest that not all anal HSIL detected in screening requires treatment. Men with persistent HPV16 were less likely to clear HSIL and are more likely to benefit from effective HSIL treatments. CLINICAL TRIALS REGISTRATION: Australia New Zealand Clinical Trials Registry (ANZCTR365383).
BACKGROUND: Gay and bisexual men (GBM) are disproportionately affected by anal cancer. Prevention is hindered by incomplete understanding of the natural history of its precursor, anal high-grade squamous intraepithelial lesions (HSIL). METHODS: The Study of the Prevention of Anal Cancer, conducted between 2010 and 2018, enrolled human immunodeficiency virus (HIV)-positive and HIV-negative GBM aged ≥35 years. Anal cytology and high-resolution anoscopy (HRA) were performed at baseline and 3 annual visits. A composite HSIL diagnosis (cytology ± histology) was used. Cytological high-grade squamous intraepithelial lesions (cHSIL) incidence and clearance rates were calculated with 95% confidence intervals (CIs). Predictors were calculated using Cox regression with hazard ratios (HRs) and 95% CIs. RESULTS: Among 617 men, 220 (35.7%) were HIV-positive, median age 49 years. And 124 incident cHSIL cases occurred over 1097.3 person-years (PY) follow-up (11.3, 95% CI 9.5-13.5 per 100 PY). Significant bivariate predictors of higher incidence included age <45 years (HR 1.64, 95% CI 1.11-2.41), HIV positivity (HR 1.43, 95% CI .99-2.06), prior SIL diagnosis (P-trend < .001) and human papillomavirus (HPV)16 (HR 3.39, 2.38-4.84). Over 695.3 PY follow-up, 153 HSIL cleared (clearance 22.0, 95% CI 18.8-25.8 per 100 PY). Predictors were age < 45 years (HR 1.52, 1.08-2.16), anal intraepithelial neoplasia (AIN)2 rather than AIN3 (HR 1.79, 1.29-2.49), smaller lesions (HR 1.62, 1.11-2.36) and no persistent HPV16 (HR 1.72, 1.23-2.41). There was 1 progression to cancer (incidence 0.224, 95% CI .006-1.25 per 100 PY). CONCLUSION: These data strongly suggest that not all anal HSIL detected in screening requires treatment. Men with persistent HPV16 were less likely to clear HSIL and are more likely to benefit from effective HSIL treatments. CLINICAL TRIALS REGISTRATION: Australia New Zealand Clinical Trials Registry (ANZCTR365383).
Authors: Elaina Kaufman; Tyler Williamson; Marie-Hélène Mayrand; Ann N Burchell; Marina Klein; Louise Charest; Sophie Rodrigues-Coutlée; François Coutlée; Alexandra de Pokomandy Journal: PLoS One Date: 2022-05-19 Impact factor: 3.752
Authors: Yoojin Choi; Mona Loutfy; Robert S Remis; Juan Liu; Anuradha Rebbapragada; Sanja Huibner; Jason Brunetta; Graham Smith; Tatjana Reko; Roberta Halpenny; Rupert Kaul; Troy Grennan Journal: Sci Rep Date: 2021-02-26 Impact factor: 4.379
Authors: Fernando Dias Gonçalves Lima; Ramon P van der Zee; Stèfanie Dick; Carel J M van Noesel; Johannes Berkhof; Maarten F Schim van der Loeff; Jan M Prins; Renske D M Steenbergen; Henry J C de Vries Journal: BMJ Open Date: 2022-08-03 Impact factor: 3.006
Authors: Alan G Nyitray; Vanessa Schick; Michael D Swartz; Anna R Giuliano; Maria E Fernandez; Ashish A Deshmukh; Timothy J Ridolfi; Christopher Ajala; Bridgett Brzezinski; Micaela Sandoval; Belinda Nedjai; Jennifer S Smith; Elizabeth Y Chiao Journal: BMJ Open Date: 2021-06-29 Impact factor: 2.692
Authors: Ramon P van der Zee; Chris J L M Meijer; Tamzin Cuming; Alexander Kreuter; Miekel M van de Sandt; Wim G V Quint; Henry J C de Vries; Jan M Prins; Renske D M Steenbergen Journal: Int J Cancer Date: 2021-08-04 Impact factor: 7.316